Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Is VBI Vaccines Stock a Buy?

TheMotleyFool

0 0

Coming into 2020, you might have expected the only really big story for VBI Vaccines (NASDAQ: VBIV) would be Sci-B-Vac, its hepatitis B vaccine. While the company has certainly achieved progress in that realm, investors' attention has focused largely on VBI's new vaccine candidate, which targets three types of coronavirus: SARS, MERS, and SARS-CoV-2 (the virus that causes COVID-19).

Both stories have translated into good news for VBI Vaccines this year. The biotech stock is up over 130% year to date in August (down from July, when it skyrocketed by as much as 347% over its January 2020 price). But is VBI Vaccines stock a buy now?

Image source: Getty Images.

Source Fool.com

Like: 0

VBIV

Share